Rossari Biotech Limited Latest Updates

$ROSSARI Q1 FY27 Revenue Growth & Earnings Outcomes In its financial statements released for the first quarter ended June 30, 2026 (Q1 FY27), the specialty chemical manufacturer reported a 28.23% year-on-year surge in consolidated operational revenue to ₹697.20 crore. Consolidated net profit (PAT) experienced a modest 4.46% YoY expansion to hit ₹35.10 crore. Sequentially, net profit declined 23.6% from the ₹45.97 crore logged in the preceding quarter (Q4 FY26). Input Cost Volatility & Margin Shifts During Q1 FY27, the company encountered minor profitability headwinds, with its operating EBITDA margins slightly compressing to 11.56%, down from 12.48% in the prior year's corresponding quarter. This margin squeeze was primarily driven by input cost inflation and an increase in total expenses, which grew 2.0% sequentially and 30.8% YoY to ₹653.18 crore. To counteract this, management initiated a rolling price pass-through mechanism across its product portfolio. Manufacturing Capacity Scaling & Chemical Arrays To secure supply integrity and fulfill multi-quarter domestic demand, Rossari’s step-down subsidiary, Unitop Chemicals, formally commissioned its newly expanded ethoxylation capacity at Dahej. This strategic expansion scales up the group's total installed ethoxylation volume threshold to 66,000 metric tons per annum, optimizing production capabilities for specialty surfactants, performance blends, and industrial chemical arrays. Corporate Governance Timeline & Non-Core Disposals The company scheduled its 17th Annual General Meeting (AGM) alongside its scheduled earnings board meeting. On the balance sheet optimization front, Rossari finalized the sale of its corporate office space in Mumbai, fetching a net inflow of ₹19 crore. The asset sale forms part of a broader corporate capital blueprint aimed at liquidating non-core holdings to self-fund future research pipeline expansions.